Tailored strategy for locally-advanced rectal carcinoma: preliminary results of a phase II multicenter trial (GRECCAR 4)

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter P. Rouanet
Citation Annals of Oncology (2016) 27 (2): 118-128. 10.1093/annonc/mdw198
Authors P. Rouanet1, E. Rullier2, B. Lelong3, P. Maingon4, J. Tuech Jean5, D. Pezet6, M. Rivoire7, B. Meunier8, S. Nougaret9, F. Castan10, C. Lemanski11, S. Gourgou12, M. Ychou13
  • 1Institut Régional du Cancer de Montpellier (ICM), Montpellier, France, /
  • 2Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France, /
  • 3Institut Paoli-Calmettes, Marseille, France, /
  • 4Centre Georges François Leclerc, Dijon, France, /
  • 5Centre Hospitalier Universitaire de Rouen, Rouen, France, /
  • 6CHU de Clermont Ferrand, Clermont Ferrand, France, /
  • 7Léon Bérard Cancer Center, Lyon, France, /
  • 8Centre Hospitalier Universitaire de Rennes, Rennes, France, /
  • 9Centre Hospitalier Universitaire de Montpellier, Montpellier, France, /
  • 10n/a, n/a, /
  • 11n/a, n/a, Alberta, /
  • 12Comprehensive Cancer Centre, and Data Center for Cancer Clinical Trials, Montpellier, France, /
  • 13CRLC Val d'Aurelle, Montpellier, France, /


Locally-advanced rectal carcinomas (LARC) raise the issues of oncologic control and therapeutic morbidity. Preoperative chemoradiotherapy (CRT) followed by total mesorectal excision has become the standard in LARC treatment. We designed a multicenter randomized trial (GRECCAR 4) to evaluate the feasibility of a tailored management of LARC according to the early tumor response to a short and intensive induction trichemotherapy (TCT), while respecting a minimal 90% R0 resection rate in all arms.